On Friday, Phathom Pharmaceuticals Inc (NASDAQ: PHAT) opened lower -8.86% from the last session, before settling in for the closing price of $18.50. Price fluctuations for PHAT have ranged from $6.07 to $19.71 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -38.36% at the time writing. With a float of $37.56 million, this company’s outstanding shares have now reached $57.97 million.
Let’s look at the performance matrix of the company that is accounted for 452 employees. In terms of profitability, gross margin is 85.02%, operating margin of -1096.02%, and the pretax margin is -966.38%.
Phathom Pharmaceuticals Inc (PHAT) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Phathom Pharmaceuticals Inc is 45.07%, while institutional ownership is 55.01%. The most recent insider transaction that took place on Jul 15 ’24, was worth 127,760. In this transaction Chief Operating Officer of this company sold 10,901 shares at a rate of $11.72, taking the stock ownership to the 240,421 shares. Before that another transaction happened on Jul 15 ’24, when Company’s CFO and CBO sold 4,325 for $11.72, making the entire transaction worth $50,689. This insider now owns 99,447 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -1.39 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -1.08) by -0.31. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -38.36% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Check out the current performance indicators for Phathom Pharmaceuticals Inc (PHAT). In the past quarter, the stock posted a quick ratio of 5.68. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 39.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.69, a number that is poised to hit -1.20 in the next quarter and is forecasted to reach -4.10 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) saw its 5-day average volume 1.08 million, a positive change from its year-to-date volume of 0.82 million. As of the previous 9 days, the stock’s Stochastic %D was 47.53%. Additionally, its Average True Range was 1.29.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 71.19%, which indicates a significant increase from 34.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.68% in the past 14 days, which was higher than the 64.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.28, while its 200-day Moving Average is $12.06. Nevertheless, the first resistance level for the watch stands at $18.34 in the near term. At $19.82, the stock is likely to face the second major resistance level. The third major resistance level sits at $20.59. If the price goes on to break the first support level at $16.09, it is likely to go to the next support level at $15.31. Assuming the price breaks the second support level, the third support level stands at $13.83.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
There are currently 59,594K shares outstanding in the company with a market cap of 1.05 billion. Presently, the company’s annual sales total 680 K according to its annual income of -201,590 K. Last quarter, the company’s sales amounted to 7,320 K and its income totaled -91,450 K.
